BOCA RATON, Fla., July 18 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) today announced that it will report its
2007 second quarter financial results on Wednesday, August 1, 2007, after
market close. The company will host a live webcast at 4:30 p.m. EDT that
day to discuss these results.
The live webcast can be accessed at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-
eventDetails&c=100445&eventID=1603855
or via the Nabi Biopharmaceuticals website at http://www.nabi.com.
If you do not have Internet access, the U.S./Canada call-in number is
(800) 638-5439, conference code 14030912, and the international call-in
number is (617) 614-3945, conference code 14030912. An audio replay will be
available for U.S./Canada callers at (888) 286-8010, conference code
74258104, and for international callers at (617) 801-6888, conference code
74258104.
An archived version of the webcast will be available at the same
Internet address through August 8, 2007. The audio replay also will be
available through August 8, 2007. The press release will be available on
the company's website at http://www.nabi.com.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. The company has one product on the market
today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)]. Nabi
Biopharmaceuticals is focused on developing products that address unmet
medical needs and offer commercial opportunities in our core business
areas: Hepatitis and transplant, Gram- positive bacterial infections and
nicotine addiction. The company has recently announced the formation of the
first of two strategic business units: Nabi Biologics. Nabi Biologics has
responsibility for the company's protein and immunological products and
development pipeline, including Nabi-HB. The second business unit, Nabi
Pharmaceuticals, is expected to be formed later this year and will have
responsibility for the NicVAX(R) (Nicotine Conjugate Vaccine) and
StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine)
development programs, as well as for the continuing milestone-related
clinical development obligations following the sale of PhosLo(R) (calcium
acetate). For a complete list of pipeline products, please go to:
http://www.nabi.com/pipeline/index.php. The company is headquartered in
Boca Raton, Florida. For additional information about Nabi
Biopharmaceuticals, please visit our Web site: http://www.nabi.com.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
http://www.nabi.com/pipeline/index.php/
CONTACT:
Investor Relations, +1-561-989-5800
|
